Gastrointestinal Drugs Companies

Takeda Pharmaceutical Company Limited Received FDA approval for Entyvio® (vedolizumab) for the treatment of ulcerative colitis in pediatric patients aged 6 years and above, expanding their market reach and patient access. Partnered with research institutions to develop next-generation therapies for IBD and other GI conditions.

AbbVie Launched Humira® (adalimumab) biosimilar for the treatment of various GI disorders, offering a more affordable alternative for patients and healthcare systems. Focused on expanding their portfolio of biosimilars and biologics for chronic disease management.

Johnson & Johnson Announced the Phase 3 development program for Stelara® (ustekinumab) for the treatment of eosinophilic esophagitis, aiming to address a high unmet need in this patient population. Collaborated with patient advocacy groups to raise awareness and improve diagnosis of rare GI diseases.

Pfizer Launched Xeljanz® (tofacitinib) for the treatment of moderate-to-severe ulcerative colitis, offering a new oral medication option for managing this chronic condition. Focused on developing innovative small molecule drugs for diverse GI disorders.

AstraZeneca Partnered with Roivant Sciences to commercialize RVT-3101, a novel oral therapy for ulcerative colitis, expanding their pipeline and market presence in IBD treatment. Invested in research and development of precision medicine approaches for personalized GI care.

• Takeda Pharmaceuticals


• Allergan Plc


• Novo Nordisk A/S


• AstraZeneca Plc


• AbbVie Inc.


• Valeant Pharmaceuticals Inc.


• Johnson & Johnson


• Bayer AG


• Boehringer Ingelheim GmbH


• GlaxoSmithKline Plc.


• Janssen Biotech Inc.


• Sanofi